Navigation Links
QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
Date:5/4/2010

Data Demonstrate Dual-Opioid(TM) Provides Significantly Better Pain Relief Compared to Component Doses; Study Goals and Secondary Endpoints Met

BEDMINSTER, N.J. and SYDNEY, Australia, May 4 /PRNewswire/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy.  Required for New Drug Application (NDA) submission with the United States Food and Drug Administration (FDA), this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.  MoxDuo IR not only demonstrated statistically superior analgesic effect compared to component doses of morphine (p=0.01) and oxycodone (p=0.01) but, also, a favorable side effect profile despite delivering twice the opioid dose of its individual components. The trial enrolled 522 patients at 6 US clinical research sites. Primary and secondary endpoints were met.

"While the initial trial data demonstrated the superiority of MoxDuo IR in terms of analgesic effect, further analysis revealed equally important findings in terms of superior overall pain relief, reduced reliance on supplemental analgesia and strong tolerability," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma.  "These findings are consistent with earlier comparative data and reinforce both the clinical benefit and commercial potential of MoxDuo IR – our lead Dual-Opioid product candidate."  

The primary endpoint for evaluating the efficacy of MoxDuo IR 12 mg/8 mg versus its milligram compon
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
2. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
3. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
4. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
5. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
6. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
7. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
8. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
9. BetterInvesting Magazine Releases Julys Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
10. QRS Diagnostic Releases 64-bit and Windows(R) 7 Compatible Software
11. BioVigil Releases Second-Generation Hand Hygiene Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... N.J., July 29, 2014  Covance Inc. (NYSE: ... quarter ended June 30, 2014.  Net revenue was $639 ... 2013.  On a GAAP basis, the company reported earnings ... The company reported pro forma earnings per diluted share ... 2013. Pro forma results exclude asset impairment charges totaling ...
(Date:7/29/2014)... 29  2014 ISPE—the International Society for Pharmaceutical ... Bournas as President and CEO, succeeding ... the Society last fall.  Mr. Bournas takes the ... healthcare association industry as well as significant international ... vision for the expansion of its global initiatives ...
(Date:7/29/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence ... Clinical Lab Expo today by unveiling two booths (#1209 ... partnering with customers to redefine the value of the ... that they,re looking for a partner to help them ... offices," said Jack Phillips , president and CEO ...
Breaking Medicine Technology:Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
... -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... in-vitro diagnostic ("IVD") company, today announced that its ... ("GP Medical") and Beijing Yuande Bio-Medical Engineering Co., ... 415th, respectively, in the Deloitte Technology Fast 500 ...
... SUNNYVALE, Calif., Dec. 5, 2010 Pharmacyclics, Inc. (Nasdaq: ... Chronic Lymphocytic Leukemia (CLL) presentations at the American Society ... PCI-32765.  Two presentations report preclinical data, and one presentation ... patients with CLL or Small Lymphocytic Lymphoma (SLL) treated ...
Cached Medicine Technology:China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 7
(Date:7/29/2014)... Kansas City, MO (PRWEB) July 30, 2014 ... care practices have recently been awarded the Patient-Centered ... bestowed by the National Committee for Quality Assurance. ... has achieved NCQA Level I, Level 2, or ... doctors who participate in Patient-Centered Medical Home report ...
(Date:7/29/2014)... 2014 1Heart Caregiver Services’ advocacy ... focus on Brain Fitness Education brings great acceptance ... Fitness Program Director Tee Barr delivered an exceptional ... unit and the Assisted Living section of Aegis ... Director Christy Rozsa and Aegis Life Neighborhood Director ...
(Date:7/29/2014)... 2014 VogueQueen.com, a well-known online supplier, ... newest trends in garment fashion by providing graceful and ... selling an all-inclusive array of sexy dresses , ... a lot of customers take price into consideration. Worry ... makes the purchase more affordable for all clients. ...
(Date:7/29/2014)... 29, 2014 Daily Gossip indicates that ... all other disturbing symptoms that hemorrhoids commonly causes. The ... and natural medicine expert. , The author of ... the elimination of symptoms such as itching, burning, pain ... more about the H Miracle by visiting the official ...
(Date:7/29/2014)... (EA) a form of acupuncture where a ... acupuncture needles produces significant improvements in fatigue, ... weeks for early stage breast cancer patients experiencing ... inhibitors (AIs) to treat breast cancer. The results ... led by researchers at the Perelman School of ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2Health News:H Miracle Review Exposes Natural Method to Cure Hemorrhoids 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3
... New research shows a link between use of two ... used either pesticide developed Parkinson,s disease approximately 2.5 times ... a collaborative effort conducted by researchers at the National ... of the National Institutes of Health, and the Parkinson,s ...
... Reinberg HealthDay Reporter , SUNDAY, Feb. 13 ... antioxidants called flavonoids, especially berries, may be protecting themselves ... In addition to berries, flavonoids are found in a ... fruits. These compounds have been touted as protective against ...
... 12 (HealthDay News) -- Winter couch potatoes who decide to ... injury if they don,t take the proper steps to safely ... an exercise program or new sport, you need to get ... fitness, advised Dr. Anders Cohen, chief of neurosurgery and spine ...
... HealthDay Reporter , FRIDAY, Feb. 11 (HealthDay ... regularly, their ability to think, to plan and even ... In addition, exercise was linked to increased activity in ... and self-control, according to brain imaging scans analyzed by ...
... 11 (HealthDay News) -- In addition to the ... one dermatologist cautions that players may be sharing ... "Outbreaks of ringworm, herpes and methicillin-resistant Staphylococcus aureus ... and professional level throughout the world," dermatologist Dr. ...
... the enzyme that gives fireflies their glow, enables researchers ... thereby track the progression of infectious diseases or cancerous ... shave their fur. Developed by researchers with the Lawrence ... California (UC) Berkeley, this new bioluminescent probe has already ...
Cached Medicine News:Health News:NIH study finds 2 pesticides associated with Parkinson's disease 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 2Health News:Berries May Offer Sweet Protection Against Parkinson's Disease 3Health News:Get Into Shape Before Spring Activities, Doctor Advises 2Health News:Overweight Kids Who Exercise Improve Thinking, Math Skills: Study 2Health News:Overweight Kids Who Exercise Improve Thinking, Math Skills: Study 3Health News:Skin Infections Can Spread Easily Among Athletes 2Health News:Skin Infections Can Spread Easily Among Athletes 3Health News:Firefly glow: Berkeley Lab scientists develop a hydrogen peroxide probe based on firefly luciferin 2Health News:Firefly glow: Berkeley Lab scientists develop a hydrogen peroxide probe based on firefly luciferin 3
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Periosteal elevator #9, 18 cm, 7"....
Full curve periosteal elevator - cervical - sharp, round tip, length 184 mm (7 1/4")....
... The Frontier Anterior Deformity System ... Kass, Moss Miami, and Isola ... thoracoscopic procedures to deliver unsurpassed versatility, ... the highest level of versatility for ...
Medicine Products: